Print

Purpose

the purpose of this study is to compare opioid consumption in morphine equivalents between the groups that received postoperative analgesia with intrathecal morphine versus US guided QL blocks versus US guided QL catheters

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Elective C section via Pfannenstiel incision - Living singleton pregnancy - Gestation week at least 37 weeks - American Society of Anesthesiologists (ASA) status 1, 2 and 3 - Primary and secondary C sections

Exclusion Criteria

  • Chronic pain - Opioid tolerant patients - Allergy to drugs used in the study. - Cognitive dysfunction - BMI > 40 - Coagulation disorder - Local infection - Inability to tolerate oral medication - Previous intra-abdominal surgery - Patients who will receive a combined spinal epidural for their C section - Local anesthetics injected at any other fascial plane except the QLB plane (for e.g.- local wound infiltration by surgeon) - Patients who received sedation or general anesthesia during their C section (midazolam, ketamine, fentanyl, propofol, hydromorphone)

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Supportive Care
Masking
Double (Participant, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Group 1 (Control group)
  • Drug: Intrathecal morphine sulfate (ITM)
    Spinal anesthesia with ITM + US guided QLB single shot sham block + QLB catheters with no continuous infusion
Experimental
Group 2(Bupivacaine hydrochloride group)
  • Drug: Bupivacaine hydrochloride
    Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters with no continuous infusion
Experimental
Group 3 (ropivacaine hydrochloride group)
  • Drug: ropivacaine hydrochloride
    Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters continuously infusing 0.2% ropivacaine hydrochloride

More Details

Status
Terminated
Sponsor
The University of Texas Health Science Center, Houston

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.